LY3462817

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LY3462817, covering 2023-02-01 to 2023-02-01. Get the full timeline:

Most recent: Clinical Trial Update: A Study of LY3462817 in Participants With Rheumatoid Arthritis [Phase 2]